Gradient Investments LLC Purchases Shares of 23,890 Merit Medical Systems, Inc. $MMSI

Gradient Investments LLC purchased a new position in Merit Medical Systems, Inc. (NASDAQ:MMSI) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm purchased 23,890 shares of the medical instruments supplier’s stock, valued at approximately $1,657,000.

A number of other large investors have also made changes to their positions in MMSI. AQR Capital Management LLC raised its stake in shares of Merit Medical Systems by 7.3% in the first quarter. AQR Capital Management LLC now owns 16,361 shares of the medical instruments supplier’s stock valued at $1,730,000 after purchasing an additional 1,114 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in Merit Medical Systems by 16.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 719,313 shares of the medical instruments supplier’s stock valued at $76,039,000 after buying an additional 103,878 shares during the period. EverSource Wealth Advisors LLC raised its stake in shares of Merit Medical Systems by 745.9% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 922 shares of the medical instruments supplier’s stock valued at $86,000 after buying an additional 813 shares in the last quarter. First Trust Advisors LP lifted its holdings in shares of Merit Medical Systems by 24.8% during the 2nd quarter. First Trust Advisors LP now owns 59,215 shares of the medical instruments supplier’s stock worth $5,535,000 after acquiring an additional 11,770 shares during the period. Finally, Cerity Partners LLC boosted its position in shares of Merit Medical Systems by 9.1% during the 2nd quarter. Cerity Partners LLC now owns 3,019 shares of the medical instruments supplier’s stock valued at $282,000 after acquiring an additional 251 shares in the last quarter. Institutional investors and hedge funds own 99.66% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the company. Wells Fargo & Company increased their target price on Merit Medical Systems from $74.00 to $83.00 and gave the stock an “equal weight” rating in a report on Friday, July 31st. BTIG Research boosted their price target on Merit Medical Systems from $100.00 to $105.00 and gave the company a “buy” rating in a research note on Friday, July 31st. JPMorgan Chase & Co. upped their price target on Merit Medical Systems from $77.00 to $95.00 and gave the company an “overweight” rating in a research report on Friday, July 31st. Citigroup reiterated an “outperform” rating on shares of Merit Medical Systems in a research note on Monday, April 20th. Finally, Needham & Company LLC lifted their price objective on Merit Medical Systems from $90.00 to $101.00 and gave the company a “buy” rating in a report on Friday, July 31st. Eight investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, Merit Medical Systems presently has an average rating of “Moderate Buy” and a consensus target price of $100.30.

Merit Medical Systems Stock Performance

MMSI opened at $89.04 on Monday. Merit Medical Systems, Inc. has a 1-year low of $59.74 and a 1-year high of $94.75. The stock has a market capitalization of $5.32 billion, a PE ratio of 36.79, a PEG ratio of 2.24 and a beta of 0.48. The company has a current ratio of 4.20, a quick ratio of 2.79 and a debt-to-equity ratio of 0.44. The firm has a 50-day moving average price of $72.21 and a two-hundred day moving average price of $71.90.

Merit Medical Systems (NASDAQ:MMSI) last announced its earnings results on Thursday, July 30th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.96 by $0.23. Merit Medical Systems had a net margin of 9.22% and a return on equity of 13.75%. The company had revenue of $418.84 million for the quarter, compared to analyst estimates of $405.25 million. During the same period in the prior year, the business earned $1.01 earnings per share. Merit Medical Systems’s quarterly revenue was up 9.5% on a year-over-year basis. Merit Medical Systems has set its FY 2026 guidance at 4.250-4.350 EPS. As a group, equities analysts anticipate that Merit Medical Systems, Inc. will post 3.81 earnings per share for the current fiscal year.

Merit Medical Systems Company Profile

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.